Sectioning technique
Trump Administration Pauses Pharmaceutical Tariffs to Negotiate Industry Agreements
Trump; pharmaceutical tariffs; tariff pause; drug pricing; domestic manufacturing; Section 232 investigation; branded drugs; patented drugs
Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries
Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices
Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift
pharmaceutical tariffs; tariff exemptions; Trump administration; Section 232 investigation; trade policy; reciprocal tariffs; generic pharmaceuticals; active pharmaceutical ingredients; commerce secretary authority
Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted
15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation
Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days
Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis
Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal
Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies
Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns
U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs
U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact